Abstract:The development of an effective human immunodeficiency virus (HIV-1) vaccine is a high global health priority. Soluble native-like HIV-1 envelope glycoprotein trimers (Env), including those based on the SOSIP design, have shown promise as vaccine candidates by inducing neutralizing antibody responses against the autologous virus in animal models. However, to overcome HIV-1’s extreme diversity a vaccine needs to induce broadly neutralizing antibodies (bNAbs). Such bNAbs can protect non-human primates (NHPs) and humans from infection. The prototypic BG505 SOSIP.664 immunogen is based on the BG505 env sequence isolated from an HIV-1-infected infant from Kenya who developed a bNAb response. Studying bNAb development during natural HIV-1 infection can inform vaccine design, however, it is unclear to what extent vaccine-induced antibody responses to Env are comparable to those induced by natural infection. Here, we compared Env antibody responses in BG505 SOSIP-immunized NHPs with those in BG505 SHIV-infected NHPs, by analyzing monoclonal antibodies (mAbs). We observed three major differences between BG505 SOSIP immunization and BG505 SHIV infection. First, SHIV infection resulted in more clonal expansion and less antibody diversity compared to SOSIP immunization, likely because of higher and/or prolonged antigenic stimulation and increased antigen diversity during infection. Second, while we retrieved comparatively fewer neutralizing mAbs (NAbs) from SOSIP-immunized animals, these NAbs targeted more diverse epitopes compared to NAbs from SHIV-infected animals. However, none of the NAbs, either elicited by vaccination or infection, showed any breadth. Finally, SOSIP immunization elicited antibodies against the base of the trimer, while infection did not, consistent with the base being placed onto the virus membrane in the latter setting. Together these data provide new insights into the antibody response against BG505 Env during infection and immunization and limitations that need to be overcome to induce better responses after vaccination.

Diverse priming outcomes under conditions of very rare precursor B cells

Vaccine priming of rare HIV broadly neutralizing antibody precursors in nonhuman primates

Diverse competitor B cell responses to a germline-targeting priming immunogen in human Ig loci transgenic mice

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Priming antibody responses to the fusion peptide in rhesus macaques

mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice

Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming

Affinity gaps among B cells in germinal centers drive the selection of MPER precursors

Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1

Recombinant MVA-prime Elicits Neutralizing Antibody Responses by Inducing Antigen-Specific B Cells in the Germinal Center

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice

Tissue Memory B Cell Repertoire Analysis after ALVAC/AIDSVAX B/E Gp120 Immunization of Rhesus Macaques.

Staged Induction of HIV-1 Glycan–dependent Broadly Neutralizing Antibodies

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization

Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.